PERSPECTIVE |
|
Year : 2021 | Volume
: 16
| Issue : 5 | Page : 116-120 |
|
Multi-disciplinary team approach in the management of connective tissue disease-interstitial lung disease: The way forward
Ben Rowlands1, Puja Mehta2, Harsha Gunawardena3
1 Department of Respiratory Medicine, Torbay and South Devon NHS Foundation Trust, UK 2 Division of Medicine, Centre for Inflammation and Tissue Repair, UCL Respiratory and Rheumatology, University College London Hospital, UK 3 Depertment of Rheumatology, North Bristol NHS Trust, Bristol; Academic Rheumatology, University of Bristol, UK
Correspondence Address:
Dr. Harsha Gunawardena Autoimmune CTD and Vasculitis, North Bristol NHS Trust, Bristol UK
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0973-3698.332986
|
|
Interstitial lung disease (ILD) is a heterogeneous group of diffuse parenchymal lung disorders and is a common manifestation of autoimmune connective tissue disease (CTD). In some patients, ILD is associated with a clinical spectrum, whereas in some cases it is the presenting or dominant feature. A prompt and correct diagnosis of CTD-ILD is paramount, as early recognition and intervention are essential to deliver an optimal patient pathway and clinical outcomes. This requires detailed clinical assessment of pulmonary and extra-pulmonary disease, robust autoimmune serological testing, review of radiological patterns, and appropriate treatment pathways. We describe the key components required for multidisciplinary evaluation of patients with CTD-ILD, highlighting the need for collaborative working between specialist teams to provide high-quality care.
|
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|